Current Therapeutic Uses of Thalidomide
Thalidomide is currently FDA-approved for erythema nodosum leprosum (ENL) and has established roles in multiple myeloma treatment, though it has largely been superseded by newer-generation immunomodulatory drugs in many countries. 1
FDA-Approved Indications
The only formal FDA approval for thalidomide remains erythema nodosum leprosum (ENL), a severe inflammatory complication of leprosy, where it is available through a restricted-use program due to its teratogenic risks. 2, 3
Multiple Myeloma Applications
Primary Therapy Settings
Thalidomide combined with dexamethasone is a Category 2B recommendation for newly diagnosed multiple myeloma in transplant candidates, though it has fallen out of favor compared to lenalidomide or bortezomib-based regimens. 4 The combination achieves response rates of 63% versus 41% for dexamethasone alone, but this must be weighed against significant toxicity including deep vein thrombosis (requiring prophylactic anticoagulation), peripheral neuropathy, rash, and somnolence. 5, 4
For non-transplant candidates, melphalan-prednisone-thalidomide (MPT) demonstrates combined complete response and near-complete response rates of 27.9% versus 7.2% for melphalan-prednisone alone, representing a more established role in this population. 5, 6
Maintenance Therapy
Thalidomide as maintenance therapy after autologous stem cell transplantation is a Category 1 recommendation, based on randomized trials showing improved event-free survival (56% vs 44% at 5 years) and complete response rates (62% vs 43%). 6 However, peripheral neuropathy remains a significant limiting factor for long-term use. The combination of thalidomide with prednisone for maintenance is a Category 2A recommendation. 6
Salvage Therapy
In relapsed/refractory multiple myeloma, thalidomide monotherapy induces responses in approximately 30% of patients, with 34% achieving minor, partial, or complete responses in progressive disease. 6 When combined with dexamethasone, response rates increase to approximately 50%. 5 Thalidomide-containing combination regimens like DT-PACE (dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, etoposide) are Category 2A options for aggressive relapsed disease. 6, 5
Important caveat: Thalidomide has been largely displaced by lenalidomide and pomalidomide in developed countries due to superior efficacy and tolerability profiles. 7 However, it remains a valuable option for heavily pretreated patients without access to novel therapies, those with renal failure (as it has negligible renal clearance), or patients with significant myelosuppression who cannot tolerate newer agents. 7
Other Established Uses
Beyond multiple myeloma and ENL, thalidomide has demonstrated efficacy in:
- AIDS-related Kaposi's sarcoma after HAART failure (though this is actually an indication for pomalidomide, a thalidomide analogue) 1
- Severe oral and genital ulcers associated with HIV and Behçet's disease 3
- Graft-versus-host disease (though evidence is mixed and some studies suggest increased mortality risk) 2, 8, 3
- Gastrointestinal bleeding from vascular malformations, leveraging its anti-angiogenic properties 9, 10
Critical Safety Considerations
Mandatory thromboprophylaxis is required when thalidomide is combined with dexamethasone or other chemotherapy due to significantly elevated venous thromboembolism risk. 4, 5, 6
Peripheral neuropathy is dose-limiting and potentially irreversible, requiring regular monitoring of sensory nerve action potentials before and during treatment. 3
Teratogenicity remains absolute, necessitating strict contraception requirements and enrollment in risk management programs (REMS). 1
The typical dosing ranges from 50-200 mg/day depending on indication, with lower doses often preferred to minimize neurotoxicity while maintaining efficacy. 7